Of the 40 recertification units (RUs) required for a CRNI® to recertify, at least 30 RUs must be obtained by attending any INS Meeting (live or online). Up to 10 RUs may be earned from the non INS Meeting category. The learning assets in this section have all been approved for RUs. Virtual Conferences meet the INS Meeting (internal) criteria. Webinars meet the non INS Meeting (external) criteria. All webinars are free to INS members.

CRNI® Recertification Approved

Search by Category
Search by Format
Sort By
Search by Favorites
Search by Keyword

  • Advancing Infusion Safety Through Smart Pump EHR Interoperability
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 01/29/2026 at 1:00 PM (EST)

    This session examines how smart pump–electronic health record (EHR) interoperability improves infusion safety, accuracy, and workflow efficiency. Participants will explore how bidirectional data exchange between pumps and EHRs reduces manual programming errors and enhances clinical decision-making. The discussion will highlight key technical and clinical components that support safe, reliable integration, along with real-world outcomes demonstrating error reduction and workflow optimization. Common challenges, such as data mapping, validation, and user adoption will be addressed, with practical strategies for overcoming them. Attendees will also learn how to use interoperability data and continuous quality improvement (CQI) methods to monitor performance and drive ongoing safety improvements. By the end of the session, participants will gain a clear understanding of how to implement, sustain, and optimize interoperable infusion systems.

    image

    This session examines how smart pump–electronic health record (EHR) interoperability improves infusion safety, accuracy, and workflow efficiency. Participants will explore how bidirectional data exchange between pumps and EHRs reduces manual programming errors and enhances clinical decision-making. The discussion will highlight key technical and clinical components that support safe, reliable integration, along with real-world outcomes demonstrating error reduction and workflow optimization. Common challenges, such as data mapping, validation, and user adoption will be addressed, with practical strategies for overcoming them. Attendees will also learn how to use interoperability data and continuous quality improvement (CQI) methods to monitor performance and drive ongoing safety improvements. By the end of the session, participants will gain a clear understanding of how to implement, sustain, and optimize interoperable infusion systems.

    Learning Objectives: At the conclusion of this session, learners will be able to: 

    • Understand the role of smart pumps in enhancing infusion safety
    • Recognize the benefits and challenges of interoperability with clinical systems
    • Explain how smart pump EHR interoperability enhances infusion safety and workflow efficiency
    • Identify key technical and clinical components of interoperable infusion systems
    • Summarize current evidence and outcomes from interoperability implementations
    • Recognize common challenges and strategies for maintaining safe, reliable integration
    • Utilize data and CQI methods to monitor and improve interoperable infusion practices
    • Identify best practices for drug library programming and maintenance

    Sheryl Krause, PhD, RN, CEN, ACNS-BC

    Sheryl Krause, PhD, RN, CEN, ACNS-BC, worked as a bedside nurse in oncology, obstetrics, and the emergency department for 19 years before becoming a clinical nurse specialist (CNS) in the emergency department in 2005. As a CNS, Dr Krause is passionate about ensuring that nurses have access to technology that enhances patient safety without disrupting efficient and effective workflows. She completed her PhD in Nursing with a minor in Industrial and Systems Engineering in 2024. The study of human factors in health care informed her thinking about infusion therapy practices. While in the PhD program, she led a project to implement smart pump technology and interoperability. Dr Krause presented the related outcomes at the 2023 International Symposium on Human Factors and Ergonomics in Health Care.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: January 29, 2029

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Optimizing Outcomes: Evidence-Based Approaches to Vascular Access Device Selection
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 01/28/2026 at 1:00 PM (EST)

    Selecting the appropriate vascular access device is critical when administering high-risk medications. Infusion nurses often face institutional barriers that prevent them from following evidence-based guidelines, leading to patient harm. This session provides an overview of the risks associated with incorrect device selection and introduces the INS 2024 Vesicant List as a tool for guiding safe infusion practices. Learners will explore how decision-making support tools can empower nurses to advocate for appropriate care. In this session, we will examine how clinical judgment, updated guidelines, and technology can work together to improve vascular access outcomes.

    image

    Selecting the appropriate vascular access device is critical when administering high-risk medications. Infusion nurses often face institutional barriers that prevent them from following evidence-based guidelines, leading to patient harm. This session provides an overview of the risks associated with incorrect device selection and introduces the INS 2024 Vesicant List as a tool for guiding safe infusion practices. Learners will explore how decision-making support tools can empower nurses to advocate for appropriate care. In this session, we will examine how clinical judgment, updated guidelines, and technology can work together to improve vascular access outcomes.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Review key factors that influence vascular access device (VAD) selection in clinical practice
    • Understand infusion-related considerations such as solution characteristics, administration methods, and therapy duration
    • Recognize patient and vessel-related risks associated with infusion therapy
    • Utilize educational resources to support informed, evidence-based decision-making for device selection

    Barb Nickel, APRN-CNS, CCRN, CRNI®

    Barb Nickel, APRN-CNS, CCRN, CRNI®, is a Clinical Nurse Specialist at a large health care system in the United States, responsible for staff development and process improvement to optimize outcomes in multiple areas of clinical practice, including critical care, infusion therapy, sepsis, and new graduate transition to practice. Ms Nickel has presented nationally and published in several peer-reviewed journals on infusion-related topics. She was the Chair of the 2024 INS Infusion Therapy Standards of Practice (SOP)Committee, and is now Chair of the 2027 INS SOP Committee. She also serves as Adjunct Research Fellow for Griffith University, Queensland, Australia.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: January 28, 2029

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Integrated vs Non-Integrated Peripheral IV Catheters: Evidence, Application, and Context in Clinical Practice
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 01/27/2026 at 4:00 PM (EST)

    Peripheral intravenous catheters (PIVCs) are among the most frequently used medical devices, yet the optimal choice between integrated and non-integrated systems is still debated. Despite strong conceptual advantages for integrated designs, real-world evidence has not consistently demonstrated superiority across all clinical contexts. This session will explore current evidence, practical implications, and cost–benefit considerations for device selection. Drawing on recent trials and clinical experience, we will discuss when integrated catheters may offer measurable benefit and when non-integrated devices may perform equally well. Participants will gain tools to interpret the evidence within the context of their own clinical environment and patient population

    image

    Peripheral intravenous catheters (PIVCs) are among the most frequently used medical devices, yet the optimal choice between integrated and non-integrated systems is still debated. Despite strong conceptual advantages for integrated designs, real-world evidence has not consistently demonstrated superiority across all clinical contexts.

    This session will explore current evidence, practical implications, and cost–benefit considerations for device selection. Drawing on recent trials and clinical experience, we will discuss when integrated catheters may offer measurable benefit and when non-integrated devices may perform equally well. Participants will gain tools to interpret the evidence within the context of their own clinical environment and patient population.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Describe the structural and functional differences between integrated and non-integrated PIVCs
    • Discuss current evidence regarding device performance, complications, and cost-effectiveness across different patient populations and care settings
    • Explain how contextual factors, such as insertion site, gauge, expected dwell time, and inserter experience affect PIVC outcomes and the applicability of published findings

    Joseph Bunch

    Tricia Kleidon, MNSc, RN, BNSc

    Tricia Kleidon, RN, BSc (Nursing), MNSc (Nurse Prac), PhD Cand., is a Nurse Practitioner in Paediatric Vascular Assessment and Management at Queensland Children’s Hospital and Research Fellow at University of Queensland. She is part of a dynamic clinical and research team that prides itself on achieving positive outcomes for patients and minimizing vascular access-related complications. Ms Kleidon is currently enrolled in a PhD program of research entitled “Techniques and technologies to improve PIVC [peripheral intravenous catheter] first time insertion success and reduce complications and failure.” 

    DJ Shannon, MPH, CIC, VA-BC, AL-CIP, FAPIC

    DJ Shannon, MPH, CIC, VA-BC, AL-CIP, FAPIC, has been involved in infection prevention and infectious diseases for over a decade, with experience spanning research, state public health, academics, and acute care hospitals. With a background in human biology and epidemiology, his focus is on the intersection of antimicrobial resistance, device-associated infections, and infection prevention. Mr Shannon is the 2025 Immediate Past President of Association for Professionals in Infection Control and Epidemiology (APIC) Indiana. He was a clinical reviewer for the 2021 INS Infusion Therapy Standards of Practice and a co-author of the Association for Vascular Access (AVA) Standards of Care for Peripheral Intravenous Catheters. Most recently, he served as the lead author for the APIC Implementation Guide for Preventing Catheter-Associated Bloodstream Infections (CABSIs) in Adults.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: January 27, 2029

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Immediate-Use Compounding
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 12/10/2025 at 1:00 PM (EST)

    As health-care professionals, we are entrusted with making sure that every compounded sterile preparation (CSP) is accurate and carries the lowest possible risk of contamination. It is preferred that CSPs are prepared in a pharmacy’s ISO-5 compounding suite. However, there are occasions when patient needs require us to prepare medications outside of those controlled settings. This course will take an in-depth look at the minimum requirements as well as the best practices for maintaining patient safety when sterile drugs are mixed in environments outside of a cleanroom.

    As health-care professionals, we are entrusted with making sure that every compounded sterile preparation (CSP) is accurate and carries the lowest possible risk of contamination. It is preferred that CSPs are prepared in a pharmacy’s ISO-5 compounding suite. However, there are occasions when patient needs require us to prepare medications outside of those controlled settings. This course will take an in-depth look at the minimum requirements as well as the best practices for maintaining patient safety when sterile drugs are mixed in environments outside of a cleanroom. 

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Define immediate-use compounding under USP <797> (2023)
    • Identify and understand the seven criteria that qualify preparation as an immediate-use CSP, exempting it from full USP <797> requirements
    • Describe best practices for reducing the risk of contamination when compounding for immediate use outside of ISO-5 conditions
    • Explain the distinction between compounding and preparation by approved labeling

    Maegan Brehm, PharmD

    Maegan Brehm, PharmD, is a Clinical Operations Pharmacist with WeInfuse and RxToolKit, where she promotes clinical safety initiatives. Dr Brehm graduated from the University of Nebraska Medical Center and began her career managing a high-volume retail pharmacy. She then transitioned to sterile compounding and home infusion care at Option Care Health and later to a critical access hospital in Nebraska. Her current work includes developing clinical competencies and RxWorkflow tools through RxToolKit and providing expert advice and real-world insight to the WeInfuse software engineering team. Dr Brehm brings over 12 years of experience in infusion therapy, sterile compounding, and staff education. She has a passion for improving patient safety, mentoring learners, and translating complex standards into practical solutions.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: December 10, 2028

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Novel Antibiotics: Niches, Efficacies, and Clinical Pearls
    Contains 3 Component(s), Includes Credits Recorded On: 11/12/2025

    Antibiotic resistance is of growing concern to the medical community and is associated with substantial morbidity and mortality. Accordingly, beginning in 2012, the United States federal government incentivized the development of new antibiotics. A variety of new antimicrobials have been approved over the last decade that are becoming routinely used in clinical practice. In this session, we will address the clinical data supporting the use of these antibiotics in specific clinical scenarios and identify clinical pearls germane to the infusion nurse.

    Antibiotic resistance is of growing concern to the medical community and is associated with substantial morbidity and mortality. Accordingly, beginning in 2012, the United States federal government incentivized the development of new antibiotics. A variety of new antimicrobials have been approved over the last decade that are becoming routinely used in clinical practice. In this session, we will address the clinical data supporting the use of these antibiotics in specific clinical scenarios and identify clinical pearls germane to the infusion nurse.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Describe the current landscape of antimicrobial development, approval, and use within the United States
    • Explain mechanisms of antimicrobial resistance
    • Identify newly approved antibiotics and their role in clinical care
    • Appropriately monitor a patient receiving a novel antibiotic for therapeutic appropriateness and clinical success

    Herman Johannesmeyer, PharmD, BCPS

    Herman Johannesmeyer, PharmD, BCPS, received his Doctor of Pharmacy degree from the University of Arizona in Tucson, Arizona and completed a 2-year pharmacotherapy residency at Texas Tech University Health Sciences Center in Lubbock, Texas. Dr Johannesmeyer provides didactic instruction in the University of California, Irvine School of Pharmacy and Pharmaceutical Sciences Doctor of Pharmacy curriculum within the renal and gastrointestinal pharmacotherapy courses. At the UC Irvine Medical Center, Dr Johannesmeyer works as a rounding internal medicine pharmacist, working with hospital medicine physician teams to provide optimal pharmacotherapeutic treatment plans for admitted floor-status inpatients. His research interests include corticosteroid stewardship, antibiotic stewardship, and inpatient glycemic control.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: November 12, 2028

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Exploring the Science of Antimicrobials: A Guided Journey with the Expert
    Contains 2 Component(s) Recorded On: 10/15/2025

    Selecting the right solution to provide antimicrobial protection is a critical step in IV site care and infection prevention, yet the technical considerations behind these choices are often overlooked. This webinar explores the science behind various antimicrobial solutions and provides clear guidance on when and why to use—or avoid—specific formulations. Through an evidence-based lens, participants will gain the knowledge needed to make informed, clinically sound decisions that support best practices in their institutions. Enhance your technical expertise and elevate patient care with a deeper understanding of antimicrobial solutions in IV site management.

    image

    Selecting the right solution to provide antimicrobial protection is a critical step in IV site care and infection prevention, yet the technical considerations behind these choices are often overlooked. This webinar explores the science behind various antimicrobial solutions and provides clear guidance on when and why to use—or avoid—specific formulations. Through an evidence-based lens, participants will gain the knowledge needed to make informed, clinically sound decisions that support best practices in their institutions. Enhance your technical expertise and elevate patient care with a deeper understanding of antimicrobial solutions in IV site management.

    Learning Objectives: At the conclusion of this session, learners will be able to: 

    1. Describe the science behind antimicrobials and their role in IV site preparation and management related to infection prevention
    2. Evaluate key factors that influence the selection of appropriate solutions for different clinical applications
    3. Apply best practice guidelines to choose the right antimicrobial solutions and improve IV site management outcomes

    This webinar does not offer any continuing education credits or recertification units. 

    Joseph Stoffel, BS

    Joseph (Joe) Stoffel, BS, has 25 years’ experience in the health care industry, primarily in wound care, while also having supported efforts in diagnostics, sterilization, food safety, and drug delivery. His current role includes leading new product development teams as well as refining and expanding Solventum’s capabilities in microbial biofilm testing and understanding.

  • Intravenous Smart Pumps: Addressing Accuracy Challenges and Solutions
    Contains 3 Component(s), Includes Credits Recorded On: 09/10/2025

    Intravenous (IV) smart pumps revolutionized medication delivery when they were first introduced, dramatically improving precision compared to gravity infusions. However, decades later, the same core technology has not kept pace with the increasing complexity of medications, workflows, and patient needs. This session will trace the evolution of IV smart pumps, explore the factors influencing flow rate accuracy, and discuss why historical designs present challenges in modern clinical contexts. Participants will learn how different pump technologies affect performance and identify practical strategies to minimize risk and enhance patient outcomes.

    image

    Intravenous (IV) smart pumps revolutionized medication delivery when they were first introduced, dramatically improving precision compared to gravity infusions. However, decades later, the same core technology has not kept pace with the increasing complexity of medications, workflows, and patient needs. This session will trace the evolution of IV smart pumps, explore the factors influencing flow rate accuracy, and discuss why historical designs present challenges in modern clinical contexts. Participants will learn how different pump technologies affect performance and identify practical strategies to minimize risk and enhance patient outcomes.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Articulate what flow rate accuracy means and how it can impact patient safety
    • Discuss the types of IV pump technology, their historical development, and their impact on flow rate accuracy
    • Describe clinically relevant factors that impact flow rate accuracy 
    • Discuss strategies for improving patient safety in the context of legacy design constraints and future innovations.

    Jeannine Blake, PhD, RN

    Jeannine Blake, PhD, RN, is a nurse scientist with a clinical background in surgical intensive care nursing and a passion for advancing health care innovation using an interdisciplinary nurse-engineer approach. Her research focuses on improving intravenous (IV) pumping technology accuracy, flow steadiness, and usability, with a current interest in understanding the impact of alarm management on nursing time and patient experience. She is dedicated to improving patient outcomes, streamlining nursing workflows, and integrating IV pumps more effectively into real-world clinical practices.

    Dr Blake earned her PhD in Nursing Science and completed a Postdoctoral Research Fellowship in Mechanical and Industrial Engineering at the University of Massachusetts Amherst. She is now an Assistant Professor in the Elaine Marieb College of Nursing and is affiliated with the Elaine Marieb Center for Nursing and Engineering Innovation. She continues her research mission in this role to build evidence that informs infusion practices and optimizes nursing workflows.

    Dr Blake contributes to the development of global safety standards for infusion therapy as a member of the Association for the Advancement of Medical Instrumentation (AAMI) technical information report (TIR) Infusion Standards Committee and has been an invited clinical advisor to the International Electrotechnical Commission (IEC) Infusion Standards Working Group. For her work in this space, she is the 2025 AAMI Young Professional Award winner.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: September 10, 2028

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Reducing Risk of CRBSIs in Hemodialysis Patients: A Multi-Disciplinary Approach
    Contains 2 Component(s) Recorded On: 08/14/2025

    Join us for an insightful presentation that features a patient’s perspective on living with end-stage kidney disease (ESKD) and experiencing a catheter-related bloodstream infection (CRBSI) while receiving hemodialysis through a central vascular access device (CVAD). Additionally, we will feature the perspective of a Nephrologist who manages these patients and will review the risks of CRBSIs, strategies for prevention, and ways that multi-disciplinary teams can work together to protect patients.

    image


    Join us for an insightful presentation that features a patient’s perspective on living with end-stage kidney disease (ESKD) and experiencing a catheter-related bloodstream infection (CRBSI) while receiving hemodialysis through a central vascular access device (CVAD). Additionally, we will feature the perspective of a Nephrologist who manages these patients and will review the risks of CRBSIs, strategies for prevention, and ways that multi-disciplinary teams can work together to protect patients.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Give an understanding of the challenges and risks faced by patients with ESKD who are receiving hemodialysis through a CVAD
    • Discuss the risks associated with CRBSIs and their impact on patient health and outcomes
    • Explore clinical guidelines for preventing CRBSIs and the potential role of using additional measures such as a catheter lock solution to reduce risk
    • Review clinical data on an antimicrobial lock solution that was recently approved by the US Food and Drug Administration
    • Discover ways for health care teams to collaborate to prevent CRBSIs and improve patient outcomes

    This webinar does not offer any continuing education credits or recertification units. 

    Anil K. Agarwal, MD, FACP, FASN, FNKF, FISN, FASDIN

    Anil K. Agarwal, MD, FACP, FASN, FNKF, FISN, FASDIN, is a Professor of Clinical Medicine at The University of California San Francisco and Academy Professor at Ohio State University, Columbus Ohio. He is also the Deputy Chief of Staff at San Francisco Veterans Affairs Health Care System at Fresno, California. Dr Agarwal is a passionate clinician and educator and is an internationally recognized expert in hypertension, dialysis, anemia, mineral bone disorders, and vascular access. He has conducted over 50 clinical trials, developed protocols, and published results of studies. He is a frequently sought speaker nationally and internationally.

    Dr Agarwal is Past President of the American Society of Diagnostic and Interventional Nephrology and Past Chair of the Interventional Nephrology Workgroup of the International Society of Nephrology (ISN). He has been an ISN ambassador to many countries. He is an advisor to the South Asia Board and a member of the North America and Caribbean Board of the ISN and is a member of the Fellowship Committee of the ISN. He has authored and edited the first textbook of Interventional Nephrology, as well as both editions of NephSAP on Interventional Nephrology published by the American Society of Nephrology, among over 500 publications and presentations.

    Dr Agarwal serves as editor and reviewer for several medical journals. He chaired many committees and boards, including the Medical Advisory Board of the National Kidney Foundation (NKF) of Ohio and Island Peer Review Organization (Renal Network of Ohio, Kentucky, and Indiana). He was the inaugural Chair of Clinical Scholarship for FAME at Wexner Medical Center from 2014 to 2020.

    Celina Medina

    Celina Medina is a 2-times kidney recipient. She was diagnosed with Nephrotic Syndrome at the age of 1 ½ years. She received her first kidney transplant when she was a young mother, at 26 years old. The life-saving gift came from a living related donor, her younger brother, Tony. After a successful transplant, Ms Medina was able to give birth to another beautiful daughter. Unfortunately, after 7 years, she returned to dialysis. This time around, while waiting for her peritoneal catheter to mature, she was rushed to the hospital with a severe infection. The infection was severe enough that she spent 3 days in the intensive care unit (ICU). After aggressive antibiotics, she was able to have a full recovery. She spent the next 12 years on dialysis and, finally, on May 25th of 2019, she received her 2nd transplant from an Angel Donor. Ms Medina now dedicates her time sharing her story throughout the country and advocating for organ donation. As a social worker, she spends her days helping the less fortunate, individuals experiencing homelessness, by getting them off the streets.

  • Chemotherapy Exposure Among Nurses: Patterns of Exposure, Handling Practices, and Contributing Factors
    Contains 3 Component(s), Includes Credits Recorded On: 07/16/2025

    Oncology nurses are at risk for negative health effects of exposure to hazardous chemotherapy drugs. The health effects of this occupational exposure include the increased risk for cancer, fertility problems, asthma, nausea, vomiting, and allergic reactions. Chemotherapy exposure occurs due to inadvertent contact with these drugs during handling procedures. While the rates of exposure to chemotherapy have decreased since the publication of hazardous drugs handling guidelines in the 1980s, nurses are still reporting exposure incidents. In this session, we will describe the patterns of exposure to chemotherapy and handling practices among oncology nurses based on results from a pilot survey study. Further, we will discuss the factors influencing the exposure and strategies to foster chemotherapy safety from the perspectives of nurses and nurse managers.

    Oncology nurses are at risk for negative health effects of exposure to hazardous chemotherapy drugs. The health effects of this occupational exposure include the increased risk for cancer, fertility problems, asthma, nausea, vomiting, and allergic reactions. Chemotherapy exposure occurs due to inadvertent contact with these drugs during handling procedures. While the rates of exposure to chemotherapy have decreased since the publication of hazardous drugs handling guidelines in the 1980s, nurses are still reporting exposure incidents. In this session, we will describe the patterns of exposure to chemotherapy and handling practices among oncology nurses based on results from a pilot survey study. Further, we will discuss the factors influencing the exposure and strategies to foster chemotherapy safety from the perspectives of nurses and nurse managers.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Identify patterns of exposure to chemotherapy and handling practices among oncology nurses based on results from a pilot survey study
    • Describe personal and workplace-related factors affecting hazardous chemotherapy exposure among oncology nurses 
    • Discuss strategies to foster chemotherapy safety among oncology nurses in health care settings 

    Dania Abu-Alhaija, PhD, RN

    Dania Abu-Alhaija, PhD, RN, is an Assistant Professor at the University of Cincinnati College of Nursing in the Population Health Department. She obtained the PhD Degree in Nursing from the University of Cincinnati College of Nursing. Her research interests are related to occupational health for health care workers, particularly exposure to hazardous drugs among nurses. Dr Abu-Alhaija’s work experience includes working in acute- and floor-levels medical-surgical departments, research, and academic settings. She has experience in teaching undergraduate and graduate nursing students in both clinical and didactic courses.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: July 16, 2028

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Cancer Targeted Treatment: From Molecule to Infusion
    Contains 3 Component(s), Includes Credits Recorded On: 06/03/2025

    This session will provide participants with an overview of new and unique targeted treatments for cancer, including mechanism of action, administration guidelines, and toxicity management. The presenter will use a case-based approach to reinforce the pathophysiology of driver mutations.

    This session will provide participants with an overview of new and unique targeted treatments for cancer, including mechanism of action, administration guidelines, and toxicity management. The presenter will use a case-based approach to reinforce the pathophysiology of driver mutations. 

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Describe the drivers for cancer development
    • List 4 targets for cancer treatment
    • Outline the side effects of targeted cancer treatments

    Christine Rimkus, APRN, MSN, AOCN

    Chris Rimkus has been an oncology nurse for 39 years.  She graduated from Southern Illinois University @ Edwardsville with her BSN and then in 1992 obtained her Masters in nursing with a focus in oncology from St. Louis University.  Her oncology experiences spans the practice spectrum including; inpatient, outpatient and even home infusion.  She has cared for a range of cancer patients from surgical oncology, outpatient infusion, radiation oncology and stem cell transplant. She has been a nurse educator and consultant, offering lectures and clinical consultation to both healthcare professionals and patient/caregiver groups.  Currently she works PT as an advanced practice provider at St. Louis University and PT as a chemo consultant for Metro Infusion Centers.  

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: June 3, 2028

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.